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     Type II diabetes mellitus (T2DM) is a prevalent disease in our country.  Bullard 
et al. (2018) report approximately 21 million adults have T2DM in the United 
States.  “The total estimated cost of diagnosed diabetes in 2017 is $327 billion, in-
cluding $237 billion in direct medical costs and $90 billion in reduced productivi-
ty” (Yang et al., 2018).  Treatment of T2DM is individualized to each patient based 
on their co-morbidities, fiscal responsibility, and route of administration options.  
Sulfonylureas and Glucagon-like Peptide-1s (GLP-1) are two classes of antidiabetic 
drugs that are available for use as second line treatment options after metformin.  
This review of literature is from articles published in 2008 or later found in the fol-
lowing electronic databases:  PubMed, Cochrane Database of Systematic Reviews, 
DynaMed Plus, ClincalKey, and Scopus.  Articles included randomized control tri-
als, systematic reviews, and meta analyses with participants being at least eighteen 
years old. The review found several benefits of GLP-1s for the treatment of T2DM.  
The risks of GLP-1s are not found to be as serious as the risks associated with sul-
fonylureas.  Sulfonylureas demonstrate historical data for their use and are available 
in oral forms as opposed to GLP-1s which is newer but in an injectable form only.  
Overall, GLP-1s offer greater benefits with minimal side effects that are less severe 
than sulfonylureas.  Limitations to this literature review include lack of articles hav-
ing direct reviews of GLP-1s and sulfonylureas. 
      
Keywords:  glucagon-like peptide-1, sulfonylurea, diabetes mellitus, second line 
treatment 
 
• The National Institute of Diabetes and Digestive and Kidney Diseases (n.d.) de-
fines type II diabetes mellitus (T2DM) as a chronic condition that affects the way 
your body is able to metabolize glucose. 
• With T2DM, the body is not able to maintain a normal glucose level which affects 
multiple other body systems. 
• Since there is no cure for diabetes, patients will need to control their blood glu-
cose levels with diet and exercise.  If that is not successful, antidiabetic drugs are 
utilized to supplement the body. 
• Each drug class acts on the body in a different way to achieve their effects.  Due 
to the difference in mechanisms of actions of each drug, there are different bene-
fits and risks of the drug classes. 
• The purpose of this review is to determine if sulfonylureas or GLP-1s offer more 
benefits while minimizing the adverse effects for second line treatment of adults 
with T2DM in the primary care setting. 
With an increasing number of patients getting diagnosed with T2DM and newer 
drugs being developed, selecting an appropriate drug that offers the most benefit for 
the patient can be overwhelming.  Further research is needed to identify which anti-
diabetic medication effectively lowers the A1c while providing additional benefits 
with minimal risks such as hypoglycemia. 
 
In adult patients with uncontrolled T2DM in the primary care setting, does treat-
ment with GLP-1s compared to sulfonylureas as adjuvant therapy to metformin of-
fer more benefits while minimizing adverse effects? 
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 Literature Review 
Current Treatment Guidelines for 
Adults with T2DM 
In the Agency for Healthcare Research 
and Quality (AHRQ) Comparative 
Effectiveness Review in 2016 (Maruthur 
et al., 2016) 
• Metformin plus exenatide (GLP-1) was 
 the preferred combination to lower the 
 hemoglobin A1c (based on 3 short 
 duration trials, pooled between group 
 difference 0.26%, 95% CI 0.03%-
 0.48%). 
• When considering body weight, 
 metformin plus a GLP-1 was preferred 
 (based on 4 trials, not pooled due to 
 differences in dosing, drug type, and 
 study duration; range of between group 
 differences 2.4-12.3 kg). 
 
 
• Second line treatment to reduce major cardiovascular events and mortality: 
− If ASCVD is present, GLP-1s such as empagliflozin or liraglutide are 
strongly recommended by the ADA (American Diabetes Association, 
2018). 
− If ASCVD is not present and A1c is not at goal, there is an ADA grade A 
recommendation for dual therapy, which should be selected based on 
patient factors and drug characteristics. 
Montivida, Shaw, Atherton, Stringer, and Paul (2016) 
• Sulfonylureas were the most popular second-line treatment.  GLP-1 usage for 
second-line treatment increased in 2016.  GLP-1 initiation was at the highest 
body mass index levels of all second-line treatment options. 
• Limitations:  lack of information on adherence, side effects, dosage changes, 
socioeconomic status, and insurance type. 
Mechanism of Action of Sulfonylureas and GLP-1s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Literature Review 
Benefits of GLP-1s and Sulfonylureas in the Treatment of Uncontrolled 
T2DM 
 
Chou et al. (2017) 
• Lower risk of myocardial infarcts when taking GLP-1s as compared to those 
taking sulfonylureas (OR = 0.48; 95% CI [0.27, 0.91]). 
• GLP-1s decrease several cardiovascular risk factors such as body weight, 
weight circumference, and blood pressure. 
• Limitations:  only randomized controlled trials available in English with less 
than one year follow-up. 
Courtney, Nayar, Rajeswaran, and Jandhyala (2017) 
• DURATION-1 study was able to show decrease in A1c (0.4-1.7%) and weight 
loss (0.9-5.3 kg) with long term treatment using a GLP-1. 
• Only 4-21% of those that discontinued treatment of GLP-1s was due to ad-
verse effects which tend to dissipate with continued treatment. 
• Limitations:  Types of studies reviewed and lack of comparison of two GLP-
1s. 
Courtney et al. (2017) 
• LEADER trial:   GLP-1 (liraglutide) was compared against a placebo which 
demonstrated cardiovascular benefit from the GLP-1 with fewer deaths from 
cardiovascular causes, nonfatal myocardial infarction, or nonfatal strokes 
(95% CI [0.78, 0.97]; p = 0.01). 
− A1c dropped by 0.4% in those treated with the GLP-1 (95% CI [-0.5, -
0.3]). 
− Weight loss dropped by 2.3 kg more using GLP-1 treatment (95% CI, [2.0-
2.5]). 
• ELIXA trial:  Evaluated the cardiovascular benefits of lixisenatide (GLP-1). 
− No significant difference in lixisenatide versus placebo (13.4% vs. 13.2%) 
was found regarding cardiovascular death, myocardial infarction, stroke, 
and hospitalization for unstable angina (95% CI [0.89-1.17]; p = 0.81). 
 
 
Risks of GLP1s and Sulfonylureas in the Treatment of Uncontrolled T2DM 
• Limitations to this study include a short duration of follow up and the fact that 
drug doses were not considered. 
• First line treatment:  diet and exercise 
• If not effective, the addition of metformin is recommended. 
• Chou et al. (2017), Courtney et al. (2017), and Maruthur et al. (2016) report 
the benefits of GLP-1s include decreased cardiovascular risk factors by de-
creasing weight and blood pressure. 
• Choby (2017) provides cost information identifying sulfonylureas to be more 
affordable than GLP-1s.  The affordability of medication plays a role in select-
ing an antidiabetic drug for different patient populations. 
• Currently, sulfonylureas are available as oral medications as opposed to GLP-
1s that are only available in the injectable form.  GLP-1s are offered in daily 
or once weekly dosing options.  The route of administration may affect pre-
scribing patterns depending on patient preference. 
• Gastrointestinal side effects (nausea, vomiting, and diarrhea) are the most 
commonly reported adverse effects in those who use GLP-1s.  Avoiding GLP-
1s in patient’s with a history of pancreatitis is recommended. 
 Discussion 
 Discussion 
• Choby (2017) and Maruthur et al. (2016) stated hypoglycemia and weight gain 
as the most reported adverse effects of sulfonylureas.  Douros et al. (2018) in-
dicate an increased risk of myocardial infarction, all cause mortality, and se-
vere hypoglycemia with sulfonylureas when compared to metformin mono-
therapy. 
• Maruthur et al. (2016) reported on three randomized controlled trials (n = 
2,557) with an odds ratio of 3.4-7.1 and a risk difference of 15-30%.  The 
combination of metformin and GLP-1 is favored over a metformin and sul-
fonylurea combination with a moderate strength of evidence in supporting ef-
fectiveness. 
• Overall, the review of literature demonstrates benefits of GLP-1s over sul-
fonylureas.  The adverse effects of GLP-1s may decrease with length of treat-
ment while adverse effects of sulfonylureas remain unchanged.  The cost, gas-
trointestinal side effects, and method of administration of GLP-1s be a deter-
rent for patients. 
• In clinical practice, T2DM is a diagnosis that is encountered almost daily in 
the primary care setting. 
• New treatment options continue to be developed to improve the management 
of adults with T2DM. 
• Between the dosage of medication, class of medication, adverse effects, and 
affordability of the medications, it may take multiple clinic visits to be obtain 
diabetic control before the possibility of the body changing and needing to 
find the necessary balance again. 
• Benefits of GLP-1s:  weight loss, low risk of hypoglycemia, decrease in sys-
tolic blood pressure, and cardiovascular protective benefits. 
• Risks of GLP-1s:  gastrointestinal side effects are the largest drawback and po-
tentially the biggest cause for discontinuation of this treatment, higher cost, 
and method of administration (injectable). 
• Benefits of sulfonylureas:  effective at lowering A1c, lower cost, method of 
administration (oral). 
• Risks of sulfonylureas:  weight gain, hypoglycemia when utilized as a mono-
therapy and to a less extent as a combination therapy with metformin. 
• With the future of genetic research, the potential to predict the effectiveness or 
lack of effectiveness of different medications for patients may dramatically 
change the prescribing patterns for providers treating T2DM. 
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